PACS (PACS) had the highest return in November 2025 by a mid-cap US stock, returning 175.9%.

ASSET	MONTH	% RETURN
PACS (PACS)	November 2025	175.89%
Cogent Biosciences (COGT)	November 2025	147.51%
Haemonetics (HAE)	November 2025	63.03%
McGraw Hill (MH)	November 2025	59.11%
MBX Biosciences, Inc Common Stock (MBX)	November 2025	57.06%
NGL Energy Partners (NGL)	November 2025	56.03%
Kohl's (KSS)	November 2025	53.21%
Scholar Rock (SRRK)	November 2025	49.91%
Brinker International (EAT)	November 2025	43.29%
Comstock Resources (CRK)	November 2025	42.87%
Edgewise Therapeutics (EWTX)	November 2025	42.45%
Septerna, Inc Common Stock (SEPN)	November 2025	42.12%
Madrigal Pharmaceuticals (MDGL)	November 2025	41.59%
Progyny (PGNY)	November 2025	40.94%
Seaboard (SEB)	November 2025	40.9%
Zymeworks Inc Common Stock (ZYME)	November 2025	40.58%
Nurix Therapeutics (NRIX)	November 2025	38.99%
Aya Gold & Silver Inc Common Shares (AYA)	November 2025	38.64%
Allied Gold (AAUC)	November 2025	37.7%
10X Genomics (TXG)	November 2025	37.6%
Teradata (TDC)	November 2025	37.49%
Compass (COMP)	November 2025	37.47%
Abercrombie & Fitch (ANF)	November 2025	37.15%
Tango Therapeutics (TNGX)	November 2025	37.06%
Viridian Therapeutics (VRDN)	November 2025	36%

Mid-cap stocks are treated as having a market cap between $2B and $10B.